Recap - Despite this asset class having just entered human testing, there’s significant excitement surrounding the therapeutic potential of blocking CD47 and the “DO NOT EAT” signal … Continue Reading
Read nowInsights - Synergy Pharmaceuticals (SGYP) cleared out a major overhang on Wednesday Oct. 28 – evidenced by the stock’s 15% move higher in the session – with the … Continue Reading
Read nowInsights - Synergy Pharmaceuticals (SGYP) is getting some much-needed love with phase 2 data for the company's lead drug candidate, plecanatide in Irritable Bowel Syndrome (IBS-C).
Read nowRecap - Great news for longtime PropThink readers on Monday morning – BioDelivery Sciences (BDSI) announced positive results from the second of two phase 3 studies testing BEMA-Buprenorphine in chronic pain … Continue Reading
Read nowInsights - Following an end-of-phase 2 meeting with the FDA, Synergy Pharmaceuticals (SGYP) will begin two phase 3 studies of plecanatide, the company’s lead drug candidate, in Irritable … Continue Reading
Read nowRecap - We count at least nine failures of one sort or another (Complete Response Letters, failed trials) in the last five days from companies such as Pozen (POZN), … Continue Reading
Read nowResearch - Synergy's phase 2 IBS-C results were, in our view, better than expected. But the market took a dim view of the stock on Wednesday for a number of reasons, outlined here.
Read now
